Trial Profile
A phase Ib study to assess the safety and tolerability of oral Ruxolitinib in combination with 5-azacitidine in patients with advanced phase myeloproliferative neoplasms (MPN), including myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) arising from MPN
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Mar 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Ruxolitinib (Primary)
- Indications Acute myeloid leukaemia; Essential thrombocythaemia; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders; Polycythaemia vera
- Focus Adverse reactions
- Acronyms PHAZAR
- 03 Jan 2022 Status changed from active, no longer recruiting to completed.
- 05 Nov 2021 Planned End Date changed from 31 Oct 2020 to 31 Dec 2021.
- 05 Nov 2021 Status changed from completed to active, no longer recruiting.